SWS Hemodialysis Care (688410.SH) forecasts a pre-reduction, with a estimated net profit of 70 million to 80 million in 2024, a decrease of 58.87% to 64.01% year-on-year.
Shanwai Mountain (688410.SH) disclosed the 2024 annual performance is expected to decrease in the performance forecast announcement. The company is expected to achieve a net profit attributable to shareholders...
Sws Hemodialysis Care (688410.SH) disclosed a performance pre-reducing announcement for the year 2024. The company expects to achieve a net profit attributable to owners of the parent company of 70 to 80 million yuan, a decrease of 58.87% to 64.01% compared to the previous year. The company also expects to achieve a net profit attributable to owners of the parent company, excluding non-recurring gains and losses, of 60 to 70 million yuan for the year 2024, a decrease of 60.25% to 65.93% compared to the previous year.
Related Articles
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
